Selection of an oral erythromycin product.
The chemistry, bioavailability, and adverse effects of erythromycin base, stearate, estolate, and ethylsuccinate are reviewed. Criteria for the evaluation of erythromycin bioavailability studies include study design, patient population, meal composition and timing, and assay methodology. Based on these criteria, the bioavailability of individual erythromycin products are evaluated in this paper. Compared with other antibiotics, the erythromycins have a good safety record. However, both the estolate and ethylsuccinate forms of erythromycin may cause hepatotoxity. Considering bioavailability and adverse effect data, a specific brand of enteric-coated erythromycin base tablets is recommended for erythromycin-sensitive infections in adults. For pediatric patients, a liquid formulation of erythromycin estolate or erythromycin ethylsuccinate is recommended.
D000284:Administration, Oral; D001682:Biological Availability; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004304:Dosage Forms; D004917:Erythromycin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D004918:Erythromycin Estolate / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans
D004304:Dosage Forms; D004917:Erythromycin; D004918:Erythromycin Estolate